Drug intelligence / Profile preview

IGN301

Development stage: Discontinued
Lead developer: Novartis
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

IGN301 is a cancer vaccine developed as an anti-idiotypic monoclonal antibody designed to provoke an immune response against the Lewis Y antigen. The Lewis Y antigen is a carbohydrate molecule highly expressed on the surface of various epithelial tumors. By mimicking this tumor-associated antigen, IGN301 stimulates the immune system to recognize and attack cancer cells expressing Lewis Y. The drug was primarily investigated for use in neoplasms (solid tumors), particularly epithelial cancers[1][2][3][4].

Targets

LeY (Lewis Y antigen)

Beyond the preview

Go deeper on IGN301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGN301.

Explore the full profile